
|Videos|March 12, 2022
Dr. Eric Klein on the “impressive” performance of IsoPSA in recent study
Author(s)Urology Times staff
“I think the take home message is that [IsoPSA is] an easy test to use,” says Eric A. Klein, MD.
Advertisement
In this video, Eric A. Klein, MD, discusses the key takeaways of the recent Urology Practice study “IsoPSA reduces provider recommendations for biopsy and magnetic resonance imaging in men with total prostate specific antigen ≥4 ng/mL: a real-world observational clinical utility study” and also shares what research is coming for the test. Klein is Emeritus Professor and Chair of the Glickman Urological & Kidney Institute at Cleveland Clinic and Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer
5











